Regulation - Lucentis

Filter

Current filters:

Lucentis

Popular Filters

Genentech files sBLA for Lucentis for diabetic retinopathy

09-08-2014

Genentech, the biotech subsidiary of Swiss pharma major Roche, has submitted a supplemental Biologics…

BiotechnologyGenentechLucentisOphthalmicsRegulationRocheUSA

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

16-06-2014

Steven Bradshaw, a UK-based drug policy expert and former ophthalmologist, is disappointed at the news…

AvastinEuropeItalyLucentisOphthalmicsPharmaceuticalRegulationRoche

Novartis gets fourth indication, DME, for Lucentis in Japan

24-02-2014

Swiss drug major Novartis says it has received approval from Japanese regulatory bodies for a fourth…

Asia-PacificJapanLucentisNovartisOphthalmicsPharmaceuticalRegulation

NICE final guidance gives green light to Lucentis for CNV

NICE final guidance gives green light to Lucentis for CNV

27-11-2013

The UK’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

NICE gives green light to Novartis’ Lucentis for eye condition

NICE gives green light to Novartis’ Lucentis for eye condition

25-10-2013

NICE has issued final draft guidance recommending Novartis' Lucentis for people with pathological myopia.

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

Novartis' Lucentis first drug approved in EU for myopic choroidal neovascularization

05-07-2013

The European Commission has granted Swiss drug major Novartis (NOVN: VX) a new indication for Lucentis…

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

NICE "green light" for Bayer's Eylea as a treatment for wet AMD

31-05-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…

BayerEuropeEyleaLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

UK's NICE backs use of Novartis' Lucentis for diabetic macular edema

27-02-2013

Reversing an earlier negative opinion, in a final guidance issued today (February 27), the UK drugs watchdog…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

UK's NICE final guidance on Novartis' Lucentis for diabetic macular edema positive

03-01-2013

In final draft guidance issued today (4 January), the UK's drug watchdog the National Institute for Health…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

UK's NICE draft guidance backs NHS use of Lucentis in DME

05-10-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in new draft guidance…

BiotechnologyEuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Safety of Novartis' Lucentis in VI-DME confirmed with new data; efficacy in CNV

06-09-2012

New data revealed yesterday by Swiss drug major Novartis (NOVN: VX) showed that Lucentis (ranibizumab)…

DiabetesLucentisNovartisOphthalmicsPharmaceuticalRegulationResearchRoche

Roche gains FDA approval for Lucentis in diabetic macular edema

13-08-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX) announced on Friday that…

GenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Genentech gains FDA panel backing for Lucentis to treat DME

30-07-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX), revealed last week that…

BiotechnologyGenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Drug approval and launch for Novartis in China, where Quintiles expands

18-01-2012

Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State…

Asia-PacificDiabetesGalvusLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalQuintilesRegulationResearch

Back to top